MedTrace Logo

Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes

NCT06797115 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-01-28

No results posted yet for this study

Summary

Beyond their metabolic effect, SGLT-2 inhibitors reduce the risk of heart failure and have cardiovascular and nephroprotective effects, yet their exact mechanism of action remains unclear. This prospective study included 40 patients with type 2 diabetes whose physician initiated SGLT-2 inhibitor therapy. Prior to and after 4 weeks of the initiation of use of SGLT-2 inhibitors, in addition to routine clinical and laboratory measurements, hydroxyl free radical and neuropathic evaluations were performed.

Conditions

  • T2DM

Interventions

DRUG

SGLT-2 inhibitor

T2D patients for whom, in addition to administering any existing antidiabetic regimen, the treating physician decided to initiate SGLT-2 inhibitor therapy (empagliflozin or dapagliflozin) based on standard clinical indications.

Sponsors & Collaborators

  • University of Pecs

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-18
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06797115 on ClinicalTrials.gov